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E-mail address: betulkavun@gmail.com (F.B.K. ÖzbSphingolipids regulate cellular processes that are critically important in cell’s fate and function in cancer
development and progression. This fact underlies the basics of the novel cancer therapy approach. The
pharmacological manipulation of the sphingolipid metabolism in cancer therapeutics necessitates the
detailed understanding of the pathway. Two computational systems biology tools are used to identify
potential drug target enzymes among sphingolipid pathway that can be further utilized in drug design
studies for cancer therapy. The enzymes in sphingolipid pathway were ranked according to their roles
in controlling the metabolic network by metabolic control analysis. The physiologically connected reac-
tions, i.e. biologically signiﬁcant and functional modules of network, were identiﬁed by metabolic path-
way analysis. The ﬁnal set of candidate drug target enzymes are selected such that their manipulation
leads to ceramide accumulation and long chain base phosphates depletion. The mathematical tools’
efﬁciency for drug target identiﬁcation performed in this study is validated by clinically available
drugs.
 2010 Elsevier Inc. All rights reserved.1. Introduction
Sphingolipids comprise a class of complex lipids which are
abundantly found in cell membrane. These membrane lipids do
not only function as structural components of the cell membrane
but they possess important roles in signal transduction (as second
messengers) and in regulatory pathways such as cell cycle arrest,
apoptosis, senescence and differentiation. The investigation of
the processes that are regulated by bioactive sphingolipid signaling
molecules demonstrates that sphingolipids are fundamental to
cancer pathogenesis and therapeutics [1]. Ceramide, an essential
building block of sphingolipids, has been suggested to be a reason-
able key metabolite in cancer therapy inducing antiproliferative
and apoptotic responses. Many anti-cancer drugs are reported to
lead to increased endogenous ceramide levels. Ceramide’s inﬂu-
ence on cell growth is dynamically balanced by sphingosine-1-
phosphate and this balance is termed as ‘‘sphingolipid rheostat”.
In cancer cells, this dynamic balance is missing [1–8].
A novel cancer therapy approach resides on the adjustment of
the sphingolipid metabolism to accumulate ceramide and to de-
crease sphingosine-1-phosphate based on the fact of ceramide
being a ‘‘tumor-suppressor lipid” and sphingosine-1-phosphate
being a ‘‘tumor-promoting lipid”. The drugs using this fact are ex-
pected to resemble the antiproliferative and apoptotic responses inll rights reserved.
ayraktar).the cell by altering the sphingolipid levels. The advantages of such
changes are not only in cancer therapy but also, enhancement of
drug action and chemoprevention [1,6–8].
There are several newly developed synthetic inhibitors of spe-
ciﬁc enzymes involved in sphingolipid metabolism [9]. The target
enzymes of human sphingolipid pathway are serine palmitoyl
transferase, ceramide synthase, ceramidase, sphingosine kinase,
glucosylceramide synthase, 1-O-acylceramide synthase. A number
of drugs like N-4-hydroxyphenyl retinamide (4-HPR), Valspodar
(PSC 833), daunorubicin, ceramide analog (B13), saﬁngol, buty-
ldeoxynojirimycin and phenoxodiol targeting the above listed en-
zymes are in pre-clinical or clinical development [7,9–12].
Changing ceramide levels in favor of cancer therapy seems to be
a promising strategy if the developed drugs targeting the newly
identiﬁed sphingolipid enzymes are selective toward malignant
cells but not healthy cells. With some ceramidase inhibitor trials
this selectivity seems to be possible due to the hypersensitivity
of malignant cells to ceramide perturbation [7]. Another evidence
for the signiﬁcance of accumulation of ceramide in cancer cells is
that cancer cells escape from apoptosis by degrading, catabolizing
or converting ceramide [9]. Experimentalists observed elevated
levels of acid ceramidase expression in human prostate cancer cell
lines [13]. The manipulation of these cellular processes gives the
chance of developing new anti-cancer therapeutics and indeed,
forms the basics of the novel cancer therapy method [1].
The most difﬁcult step in drug discovery is the decision of the
drug target enzymes. Since clinical aspects of sphingolipids are still
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ing computational tools is a signiﬁcant requirement. Metabolic
control analysis is a powerful mathematical tool to solve this puz-
zle of drug target identiﬁcation via considering the role of individ-
ual components within a metabolic network [14]. As mentioned
previously, sphingolipids regulate processes that are vital in terms
of cell’s fate. These processes are all very important for cancer ini-
tiation, progression and treatment [6]. The identiﬁcation of critical
enzymes within sphingolipid metabolism facilitates the link be-
tween sphingolipids and cancer.
In the present study, the key points of sphingolipid metabo-
lism in terms of ceramide and sphingosine-1-phosphate are
investigated using two different mathematical frameworks, met-
abolic control analysis and metabolic pathway analysis. Meta-
bolic control analysis is based on dynamic data whereas
metabolic pathway analysis uses the stoichiometry of the system.
These two systems biology tools reveal the important metabolic
steps of the sphingolipid pathway and using this information no-
vel drug target enzymes can be recognized and potential drug
target enzymes in human pathway can be proposed. Although
the Saccharomyces cerevisiae and human sphingolipid pathways
are similar to each other, one should admit that S. cerevisiae
sphingolipid pathway consists of only few complex sphingolipids
when compared with that of mammalian cells/human. Thus, this
study can be considered as an attempt to bridge the basic sphin-
golipid research to potential medical applications in cancer
therapy.2. Computational methods
In order to gain a better understanding of sphingolipid metabo-
lism, S. cerevisiae is taken as the model system. The availability of
the detailed and complete enzymatic and genetic data of S. cerevi-
siae makes the organism eligible for computational works that can
give reliable ﬁrst guesses for human studies. The conservation of
sphingolipid metabolic and regulatory pathways across species
has been used in the identiﬁcation of the corresponding mamma-
lian orthologues [15–18]. In the present study, the protein se-
quence homologies of the enzymes that are responsible for the
sphingolipid pathway activity were cross-checked against human
(Homo sapiens) proteome via NCBI (National Center for Biotechnol-
ogy Information) protein blast utility. Almost all the enzymes in-
volved in the sphingolipid reactions of the model system have a
homolog in human proteome with a reasonable and exceptable
E-value, which shows the similarity of the two protein sequences.
Also the functional domains of the yeast and human sphingolipid
homolog proteins were compared and almost complete overlap is
observed. The de novo sphingolipid metabolism of yeast exactly
matches to that of human with the exception of the double bonded
ceramide in human which is missed in yeast cells. The complex
sphingolipids of yeast and human differ but the potential drug tar-
gets proposed in the current study correspond to mainly de novo
sphingolipid synthesis.2.1. Sphingolipid metabolic pathway
This model system consists of three parts. The main part is the
sphingolipid metabolism and the two auxiliary pathways are the
fatty acid metabolism and phospholipid metabolism. They inte-
grate sphingolipid metabolism to other cellular processes. The
fatty acid metabolism reactions used in the model system are steps
that correspond to the synthesis and elongation of fatty acids. The
very long chain fatty acids (C26-CoA) are employed as precursors in
the synthesis of dihydroceramide (DHCer) and phytoceramide
(PHCer). Phospholipid metabolism is also another importantbranch point at the initial step of sphingolipid, i.e. at palmitoyl-
coenzyme A (Pal-CoA) level. Synthesis of phosphatidyl inositol
(PI) is included in the model system due to the fact that; PI is a pre-
cursor metabolite for the synthesis of complex sphingolipid, inosi-
tol phosphorylceramide (IPC) from both dihydroceramide and
phytoceramide.
The sphingolipid metabolic pathway (Table 1) for the dynamic
model is taken from Alvarez-Vasquez et al. [19] and explained be-
low. The ﬁrst reaction of the de novo sphingolipid synthesis is the
condensation of serine and Pal-CoA via the enzyme serine palmi-
toyl transferase, r11, and takes place in the endoplasmic reticulum.
This reaction produces the precursor metabolite 3-ketodihydrosp-
hingosine (KDHS) which is required for the synthesis of the ﬁrst
long chain base, dihydrosphingosine (DHS). KDHS is rapidly re-
duced to the long chain base, r13, catalyzed by 3-ketodihydrosp-
hingosine reductase in the endoplasmic reticulum. The
condensation reaction can be named as the initializing step of de
novo sphingolipid synthesis in S. cerevisiae [2,16,17].
After the formation of the sphingoid long chain bases in S.
cerevisiae, there are two alternative paths that the long chain
bases can follow: acylation or phosphorylation. Dihydrosphingo-
sine (DHS) and phytosphingosine (PHS) are acylated to DHCer,
r23, and PHCer, r24, respectively, by ceramide synthase and the
reactions take place in endoplasmic reticulum [16,19,20]. The
enzyme responsible for the phosphorylation of the long chain
bases to long chain base phosphates is sphingoid base kinase
which catalyzes the synthesis of dihydrosphingosine-1-phosphate
(DHS-P) and phytosphingosine-1-phosphate (PHS-P), r15 and r20,
respectively. The reverse reactions, dephosphorylations, r14 and
r19, are also possible by the enzyme sphingoid-1-phosphate phos-
phatase in endoplasmic reticulum of S. cerevisiae. The phosphory-
lation and dephosphorylation steps are needed for the synthesis
of sphingolipids. The phosphorylated long chain bases can be
decomposed by the enzyme sphingosine-phosphate lyase to cyti-
dine diphosphate-ethanolamine (CDP-E), r17 and r18. At this point
sphingolipid pathway is again linked to the phospholipid path-
way [16,19].
DHCer and PHCer can be converted back to long chain bases of
DHS and PHS, r22 and r25, by dihydroceramide and phytoceramide
alkaline ceramidases in the endoplasmic reticulum [16,19].
Hydroxylation of DHS and DHCer to PHS, r21, and PHCer, r26,
respectively, are catalyzed by sphingosine hydroxylase encoded
by SUR2 in endoplasmic reticulum [20]. This enzyme is responsible
for the adjustment of balance between the two S. cerevisiae sphing-
oid long chain bases [16,19]. This step does not take place in mam-
malian cells, where dihydroceramide is desaturated to form
ceramide but not phytoceramide [1].
In S. cerevisiae three types of complex sphingolipids contain-
ing myo-inositol are synthesized: inositol phosphorylceramide
(IPC), r29 and r30, mannosylinositol phosphorylceramide (MIPC),
r39, and mannosyldiinositol phosphorylceramide (M(IP)2C), r49.
As the only alteration of ceramide in S. cerevisiae is by the
addition of inositol phosphate (IP), these three complex sphingo-
lipids are the end products of S. cerevisiae sphingolipid metabo-
lism. This modiﬁcation by IP occurs only in S. cerevisiae but not
in mammalian cells; therefore IPC, MIPC, M(IP)2C may not be
found in mammalian cells. In S. cerevisiae, complex sphingolipid
synthesis reactions are reported to occur in the Golgi apparatus
[2,16].
There are 49 irreversible reactions in S. cerevisiae sphingolipid
metabolism. The enzymes corresponding to each reaction are listed
in Table 1. Thirty-one metabolites with their abbreviations are gi-
ven in Table 2. The rate equations are taken from Alvarez-Vasquez
et al. [19] who used Biochemical Systems Theory (BST) and Gener-
alized Mass Action (GMA) representation. The rate expressions for
each reaction represent the effect of the substrate concentration,
Table 1
The list of reactions and enzymes used in metabolic control analysis (The key
reactions are indicated as bold.). It is taken from Alvarez-Vasquez et al. [19]. The
underlined reaction numbers indicate the reactions that are further studied and
developed in metabolic pathway analysis.
# Reactions Enzyme name
1 Palm? Pal-CoA Palmitoyl-coenzyme A synthase
2 Pal-CoA? PA Glycerol-3-phosphate acyltransferase
3 PA? DAG Phosphatidate phosphatase
4 PA? CDP-D Cytidine diphosphate-diacylglycerol
synthase
5 CDP-D + Inositol? PI Phosphatidyl-inositol synthase
6 G6P? Inositol Inositol-1-phosphate synthase
7 PI + ATP? Phosphoinositide kinase
8 Serine + CDP-D? PS Phosphatidyl-serine synthase
9 3PS? Serine Phosphoserine-phosphatase
10 Serine? Serine hydroxymethyl transferase
11 Pal-CoA + Serine? KDHS Serine palmitoyl transferase
12 Pal-CoA? Acyl-coenzyme A binding protein
13 KDHS? DHS Ketodihydrosphingosine reductase
14 DHS-P? DHS Sphingoid base-1-phosphate
phosphatase
15 DHS + ATP? DHS-P Sphingoid base kinase
16 PS? Phosphatidyl-serine decarboxylase
17 DHS-P? Pal-CoA + CDP-E Sphingosine-phosphate lyase
18 PHS-P? Pal-CoA + CDP-E Sphingosine-phosphate lyase
19 PHS-P? PHS Sphingoid base-1-phosphate
phosphatase
20 ATP + PHS? PHS-P Sphingoid base kinase
21 DHS? PHS Hydroxylase
22 DHCer? DHS Dihydro-ceramidase
23 C26-CoA + DHS? DHCer Ceramide synthase
24 C26-CoA + PHS? PHCer Ceramide synthase
25 PHCer? PHS Phytoceramide alkaline ceramidase
26 DHCer? PHCer Hydroxylase
27 PHCer? Glycosyphosphatidylinositol
remodelase
28 IPC? DHCer Inositol phospho-sphingolipid
phospholipase C
29 DHCer + PI? DAG + IPC Inositol phosphorylceramide synthase
30 PHCer + PI? DAG + IPC Inositol phosphorylceramide synthase
31 IPC? PHCer Inositol phospho-sphingolipid
phospholipase C
32 CDP-E + DAG? Diacylglycerol-ethanolamine
phosphotransferase
33 DAG? Diacylglycerol-choline
phosphotransferase
34 AC + CoA + ATP? Ac-CoA Acetyl-coenzyme A synthetase
35 Ac-CoA + ATP?Mal-CoA Acetyl-coenzyme A carboxylase
36 Mal-CoA + Ac-CoA? Pal-CoA Fatty acid synthethase
37 Mal-CoA + Pal-CoA? C26-CoA Very long chain fatty acid synthase
38 IPC? IPCpm Transport to plasma membrane
39 IPC?MIPC Mannosyl inositol phosphoceramide
synthase
40 MIPC? PHCer Inositol phospho-sphingolipid
phospholipase C
41 MIPC?MIPCpm Transport to plasma membrane
42 MIPC? DHCer Inositol phospho-sphingolipid
phospholipase C
43 M(IP)2C? DHCer Inositol phospho-sphingolipid
phospholipase C
44 M(IP)2C? PHCer Inositol phospho-sphingolipid
phospholipase C
45 M(IP)2C?M(IP)2Cpm Transport to plasma membrane
46 IPCpm? IPC Transport from plasma membrane
47 MIPCpm?MIPC Transport from plasma membrane
48 M(IP)2Cpm?M(IP)2C Transport from plasma membrane
49 MIPC + PI?M(IP)2C + DAG Mannosyldiinositol
phosphorylceramide synthase
Table 2
The list of metabolites and abbreviations (The key metabolites are indicated as bold.).
Metabolite abbreviations Metabolite names
3PS 3-Phosphate serine
AC Acetate
Acetyl-CoA Acetyl-coenzyme A
ATP Adenosine triphosphate
C26-CoA Hexasanoyl-CoA (n-C26:0 CoA)
CDP-DAG Cytidine diphosphate-diacylglycerol
CDP-E Cytidine diphosphate-ethanolamine
CoA Coenzyme A
DAG Diacylglycerol
DHS Dihydro-sphingosine
DHS-P Dihydro-sphingosine-1-phosphate
DHCer Dihydro-ceramide
G6P Glucose-6-phosphate
INO Inositol
IPC Inositol phosphorylceramide
IPCpm Inositol phosphorylceramide-plasma
membrane
KDHS 3-Ketodihydrosphingosine
M(IP)2C Mannosyldiinositol phosphorylceramide
M(IP)2Cpm Mannosyldiinositol
phosphorylceramide-plasma membrane
Mal-CoA Malonyl-coenzyme A
MIPC Mannosylinositol phosphorylceramide
MIPCpm Mannosylinositol
phosphorylceramide-plasma membrane
PA Phosphatidic acid
Pal-CoA Palmitoyl-coenzyme A
Palm Palmitate
PHS Phytosphingosine
PHS-P Phytosphingosine-1-phosphate
PHCer Phytoceramide
PI Phosphatidyl inositol
PS Phosphatidyl serine
SER Serine
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ple for the rate expression of a hypothetical reaction is given by the
following equation:Aþ B!X
M
C
v ¼ rate constant cp1A  cp2B  cp3M  Xp4
ð1Þ
where v is rate, cA is concentration of metabolite A, cB is concentra-
tion of metabolite B, cM is concentration of modiﬁer M, X is enzyme
activity, and p is kinetic order.2.2. Metabolic control analysis (MCA)
Metabolic control analysis [21–23] is classiﬁed as a post-geno-
mic tool to understand the principles governing a metabolic net-
work’s control which is distributed among various enzymatic
steps. In this study, metabolic control analysis was employed to
quantify the biochemical control of the enzymes constituting the
sphingolipid metabolism on the sphingolipid ﬂuxes and concentra-
tions, and hence to determine the candidate enzymes in the meta-
bolic network appropriate as drug targets for antiproliferative and
apoptotic responses.
Control coefﬁcients quantitatively describe the relative change
in the systematic parameter such as the reaction ﬂux or metabolite
concentration with respect to the enzyme activity. When the
amount of change in the enzyme activity is same as the change
in the systematic property then the control coefﬁcient is unity. A
high control coefﬁcient indicates that the change in the enzyme
activity is completely reﬂected to systematic parameter under
investigation. The same rationale applies for a low control coefﬁ-
cient such that the change in the enzyme activity has negligible ef-
fect on the systematic parameter [14].The ﬂux control coefﬁcient
(CJi) of Eq. (2a) illustrates the strength of response in the reaction
ﬂux (J), to a change in the enzyme concentration (Ei). The concen-
tration control coefﬁcient (CSi ) of Eq. (2b) illustrates the strength of
response in the metabolite concentration (S), to a change in the
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cients can take both positive and negative values; a negative con-
trol coefﬁcient indicates a negative control effect on the
concentration of the metabolite of interest.
CJi ¼
@J
@Ei
 Ei
J
¼ @ ln jJj
@ lnEi
ð2aÞCSi ¼
@S
@Ei
 Ei
S
¼ @ ln jSj
@ ln Ei
ð2bÞ
As there are various important metabolites/ﬂuxes that have to be
considered, three different algorithms were developed to apply a
selection criterion for the control coefﬁcients and to identify the vi-
tal steps of the pathway (Fig. 1). The set of key metabolites consists
of DHS, PHS, DHCer, PHCer, DHS-P, PHS-P and all complex sphingo-
lipids at the site of production and plasma membrane (pm) (IPC,
IPCpm, MIPC, MIPCpm, M(IP)2C, M(IP)2Cpm) (indicated as bold in
Table 2).
2.2.1. Selection criteria
(1) In the ﬁrst algorithm a global threshold value of 0.4 is cho-
sen for the concentration control coefﬁcients and a matrix that
consists of +1, 0 and 1 is constructed. The columns of this matrix
contain the set of selected metabolites and the rows contain the
enzymatic steps. As there are 49 enzymatic steps and 12 metabo-
lites of interest, the above described binary criterion matrix had
the dimensions of 49  12. Absolute j þ 1= 1j values were used
to represent the concentration control coefﬁcients of the metabo-
lites and reactions which are absolutely greater than the global
threshold value of 0.4. Thus, this ﬁrst algorithm does not discrim-Fig. 1. The schematic representation of three selection algorithms utilized in the analysi
in the same ﬂowchart representation whereas third algorithm is depicted in a separateinate between the negative and positive control coefﬁcients. Then
the number of non-zero elements in each row was counted and re-
corded. The enzymes for each reaction step were ranked according
to this score representing the reactions that are important for most
of the metabolites constituting the set. The enzymes (reactions)
that affect at least 50% and more of the 12 critical metabolites with
concentration control coefﬁcients higher than 0.4 were selected as
the signiﬁcant enzymes and included in the set of potential drug
targets.
The same procedure was applied to the analysis of ﬂux control
coefﬁcients. A set of critical reactions were chosen among the ones
that are producing and consuming the 12 important metabolites in
the previous step of the algorithm. These are the reactions num-
bered 13–15, 17–31, 38–49 and indicated as bold in Table 1. The
binary criterion matrix had the dimensions of 49  30 where the
columns corresponded to the selected reactions instead of the
metabolites. In the ﬁnal step of determining the potential drug tar-
get enzymes, the enzymes (reactions) that manipulate at least 50%
and more of the 30 important reactions with ﬂux control coefﬁ-
cients higher than 0.4 were selected (Fig. 1).
(2) In the second algorithm instead of using a global threshold
value for both concentration and ﬂux control coefﬁcients, local
threshold values are used for each control coefﬁcient examination.
The decision of the boundaries, i.e. the local threshold values, is
made individually according to the gaps between the coefﬁcients,
i.e. the highest differences between the coefﬁcients were taken
as break points. After the determination of the threshold values
for each control coefﬁcient, the algorithm follows as the previous
one (Fig. 1).
(3) The basic principle underlying in both algorithms was the
utilization of the threshold values and the enzymes over as and ﬁltration of metabolic control analysis results. First two algorithms are shown
ﬂowchart.
F.B.K. Özbayraktar, K.Ö. Ülgen / Journal of Biomedical Informatics 43 (2010) 537–549 541speciﬁed threshold are treated equally. In order to use the
information embedded in control coefﬁcients more efﬁciently, a
third algorithm is designed where a matrix of concentration con-
trol coefﬁcients of the selected critical metabolites is constructed
and the maximum values of the absolute control coefﬁcients in
each column is found separately. Then concentration control
coefﬁcients are normalized with respect to the absolute maxi-
mum value of each column so that the matrix at this stage con-
sists of the relative weights of the concentration control
coefﬁcients. This stage is a branch point of the algorithm where
further analysis involves two approaches, i.e. (i) overall interpre-
tation by average relative weights and (ii) apoptosis speciﬁc
analysis by relative weights.
First an overall interpretation of the weighted concentration
control coefﬁcients are performed which involves averaging the
weights for each enzymatic step without considering the direction
of action, i.e. signs of the control coefﬁcients. The important reac-
tions from average weights of both concentration control coefﬁ-
cients and ﬂux control coefﬁcients are selected by using a
threshold value of 0.5.
Second, in apoptosis speciﬁc analysis, the constructed critical
metabolite set is partitioned into two parts according to the knowl-
edge about the action of metabolites on apoptosis in mammalian
cells. As mentioned formerly, ceramide induces apoptosis whereas
sphingosine-1-phosphate promotes cell growth and proliferation.
Hence, the concentration control coefﬁcients of DHCer and PHCer
are examined separately, and the phosphorylated forms of long
chain bases are analyzed accordingly (Fig. 1).
Metabolic control analysis was performed using the software
GEPASI version 3.30 [25]. The ordinary differential equations em-
ployed in the metabolic control analysis were also solved under
Matlab R2007a using the stiff differential equation solver with
the variable order method.Fig. 2. The reaction system used in metabolic pathway analysis. In order to study the inh
[19] given in Table 1, is reconstructed; the reactions are balanced stoichiometrically a
metabolism are shown in octagon boxes; the metabolites of the phospholipids pathway
boxes show the metabolites that do not ﬁt the above classiﬁcations.2.3. Metabolic pathway analysis (MPA)
Metabolic pathway analysis is a powerful stoichiometric model-
ing approach for systems biology and used here in the identiﬁca-
tion of physiologically signiﬁcant sets of connected reactions in
sphingolipid metabolic network. In order to study the inherent
network properties, the metabolic reaction network of Alvarez-
Vasquez et al. [19] is reconstructed; the reactions are balanced
stoichiometrically using Expasy, KEGG, Brenda databases [29–31]
and the genome scale models from the literature [26–28]; and
the lumped reactions are decomposed as shown in Fig. 2.
2.3.1. Improvements in reaction system
The lumped reaction for the synthesis of C26-CoA from malo-
nyl-coenzyme A (Mal-CoA) is represented by two distinct
reactions: First Mal-CoA is converted to hexacosanoate (Hexco),
r37, and then converted to C26-CoA, r037, and Pal-CoA is no more
a substrate for this reaction. The reaction 36 is modiﬁed so that
in the newly reconstructed network, palmitate is synthesized by
r036, instead of Pal-CoA. The reaction 6 is also decomposed to
two separate reactions, ﬁrst glucose-6-phosphate (G6P) is con-
verted to inositol-1-phosphate (I1P), r6, and then it is converted
to inositol, r06.
The products of the decomposition reactions of the phosphor-
ylated long chain bases show also differences with the ones in
Alvarez-Vasquez et al.’s pathway [19]. DHS-P and PHS-P are
decomposed to ethanolamine phosphate (EP) and palmitaldehyde
(PalmA), r17 and EP and 2-hydroxy-hexadecanal (HPalmA), r18,
respectively, in the newly reconstructed network. The synthe-
sized EP from these decomposition reactions is converted to cyti-
dine diphosphate-ethanolamine (CDP-E) in Fig. 2 (r33). The
products of 17th and 18th reactions catalyzed by lyases were
Pal-CoA and CDP-E for both long chain base phosphates in theerent network properties, the metabolic reaction network of Alvarez-Vasquez et al.
nd the lumped reactions are decomposed. The metabolites involved in fatty acid
are in oval boxes, and the sphingolipids are shown in rectangular boxes. The dashed
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tions are not available in the literature and also when the ele-
ments’ balance is controlled for the products, it is impossible to
balance the elements. A new reaction is added to the metabolic
network such that the conversion of PalmA (the decomposition
reactions’ product) to palmitate, r50, and then to Pal-CoA be-
comes possible, r1.
The complex sphingolipids synthesized from DHCer and PHCer
are marked as follows: IPC produced from PHCer is named as IPC-
PH and represented as IPC-DH if it is synthesized from DHCer. The
difference of reactions 38, 39, 41, 45, 46, 47, 48 and 49 from their
primed versions are their source, i.e. whether they are produced
from DHCer or PHCer. This distinction is made to follow the two
types of long chain bases, DHS and PHS (Table 3).Table 3
The balanced reaction list with the enzymes catalyzing the reactions used in metabolic pa
# Reactions En
1 ATP + Palm + CoA? AMP + DP + Pal-CoA Pa
2 Pal-CoA + G3P? CoA + PA Gl
3 H2O + PA? DAG + P Ph
4 PA + H + CTP? CDP-DAG + DP CD
5 CDP-DAG + INO? PI + CMP + H Ph
6 G6P? I1P In
60 I1P + H2O? INO + P In
7 ATP + PI? ADP + H + P3I Ph
8 CDP-DAG + SER? CMP + H + PS Ph
9 3PS + H2O? P + SER Ph
10 SER + THF? GLY + H2O + MTHF Se
11 H + Pal-CoA + SER? KDHS + CO2 + CoA Se
12 Pal-CoA? Pal-CoAxt Ac
13 KDHS + H + NADPH? NADP + DHS 3-
14 H2O + DHS-P? P + DHS Sp
15 ATP + DHS? ADP + H + DHS-P Sp
16 H + PS? CO2 + PE Ph
17 DHS-P? EP + PalmA Sp
18 PHS-P? HPalmA + EP Ph
19 H2O + PHS-P? P + PHS Sp
ph
20 ATP + PHS? ADP + H + PHS-P Sp
21 H + NADPH + O2 + DHS? H2O + NADP + PHS Ph
22 DHCer + CoA + H? C26-CoA + DHS Di
23 C26-CoA + DHS? DHCer + CoA + H Ce
24 C26-CoA + PHS? PHCer + CoA + H Ce
25 PHCer + CoA + H? C26-CoA + PHS Ph
26 DHCer + H + NADPH + O2? PHCer + H2O + NADP Ce
27 PHCer? PHCerxt GP
28 DAG + IPC-DH? DHCer + PI In
29 DHCer + PI? DAG + IPC-DH In
30 PHCer + PI? DAG + IPC-PH In
31 DAG + IPC-PH? PHCer + PI In
32 DAG + CDP-E? CMP + H + PE Di
33 EP + CTP + H? CDP-E + DP Ph
34 ATP + AC + CoA? AMP + DP + Ac-CoA Ac
35 Ac-CoA + ATP + Carb? ADP + H + Mal-CoA + P Ac
36 Ac-CoA + 7Mal-
CoA + 14NADPH + 7H? Palm + 7CO2 + 14NADP + 8CoA + 6H2O
Fa
37 3H + Mal-CoA + 2NADPH + Tetco? CO2 + CoA + H2O + Hexco + 2NADP Ve
370 ATP + CoA + Hexco? AMP + C26-CoA + DP Ve
38 IPC-DHM IPC-DHpm Tr
380 IPC-PHM IPC-PHpm Tr
39 GDPman + IPC-DH? GDP + H + MIPC-DH M
390 GDPman + IPC-PH? GDP + H + MIPC-PH M
40 H2O + DAG + MIPC-PH? PHCer + PI + man In
41 MIPC-DHMMIPC-DHpm Tr
410 MIPC-PHMMIPC-PHpm Tr
42 H2O + DAG + MIPC-DH? DHCer + PI + man In
43 H2O + 2DAG + M(IP)2C-DH? DHCer + 2PI + man In
44 H2O + 2DAG + M(IP)2C-PH? PHCer + 2PI + man In
45 M(IP)2C-DHMM(IP)2C-DHpm Tr
450 M(IP)2C-PHMM(IP)2C-PHpm Tr
49 MIPC-DH + PI? DAG + M(IP)2C-DH M
490 MIPC-PH + PI? DAG + M(IP)2C-PH M
50 PalmA + NAD + H2O? Palm + NADH2.3.2. Elementary ﬂux modes
Metabolic pathway analysis algorithm involves the calculation
of elementary ﬂux modes of the sphingolipid system. Elementary
ﬂux modes (EFM) of a metabolic system specify all the possible
sets of enzymes that can operate without disturbing the valid stea-
dy state of the system [32–36]. These identiﬁed functional path-
ways cannot be decomposed into smaller meaningful parts and
they can be used as the linear basis for the expression of the whole
network states. The basic principles that should be satisﬁed during
computation of elementary ﬂux modes are (i) a pseudo steady state
condition, (ii) a feasibility condition and (iii) a non-decomposabil-
ity condition.
First, elementary ﬂux modes were determined using CellNetAn-
alyzer Version 6.3. [37], and then a set of key metabolites wasthway analysis.
zyme names
lmitoyl-CoA synthase
ycerol-3-phosphate acyltransferase
osphatide phosphatase
P-DAG syhthase
osphatidylinositol synthase
ositol-1-phosphate synthase
ositol producing and missing rxn
osphatidylinositol kinase
osphatidylserine synthase
osphoserine-phosphatase
rine hydroxymethyl transferase
rine C-palmitoyltransferase
yl-CoA-binding protein
Dehydrosphinganine reductase
hingoid base-phosphate phosphatase (sphinganine 1-phosphatase)
hingolipid long chain base kinase (sphinganine kinase)
osphatidylserine decarboxylase
hinganine phosphate lyase
ytosphingosine phosphate lyase
hingoid base-phosphate phosphatase (phytosphingosine 1-phosphate
osphatase)
hingolipid long chain base kinase (phytosphingosine kinase)
ytosphingosine synthesis
hydroceramide alkaline ceramidase
ramide-1 synthase (26C)
ramide-2 synthase (26C)
ytoceramide alkaline ceramidase
ramide-1 hydroxylase (26C)
I remodelase
ositol phospho-sphingolipid phospholipase C
ositol phosphorylceramide synthase (26C)
ositol phosphorylceramide synthase (26C)
ositol phospho-sphingolipid phospholipase C
acylglycerol-ethanolamine phosphotransferase
osphoethanolamine cytidylyltransferase
etyl-coenzyme A synthetase
etyl-coenzyme A carboxylase
tty acid synthetase
ry long chain fatty acid synthase
ry long chain fatty acid synthase
ansport of IPC-DH to plasma membrane
ansport of IPC-PH to plasma membrane
annose-inositol phosphorylceramide synthase (26C)
annose-inositol phosphorylceramide synthase (26C)
ositol phospho-sphingolipid phospholipase C
ansport of MIPC-DH to plasma membrane
ansport of MIPC-PH to plasma membrane
ositol phospho-sphingolipid phospholipase C
ositol phospho-sphingolipid phospholipase C
ositol phospho-sphingolipid phospholipase C
ansport of M(IP)2CDH to plasma membrane
ansport of M(IP)2CPH to plasma membrane
annosyldiinositol phosphorylceramide synthase (26C)
annosyldiinositol phosphorylceramide synthase (26C)
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signiﬁcance of ceramide and sphingosine-1-phosphate in apopto-
sis. The elementary ﬂux modes in that all these key metabolites
participate are selected. The reactions that are common in all the
selected elementary ﬂux modes are identiﬁed and the enzymes
catalyzing these common reactions are noted as candidate poten-
tial drug targets. The selection of the EFMs that all the elements
of the key set participate in and the common reactions occurring
in these EFMs is performed by an algorithm coded in MATLAB
R2007a.
2.3.3. Control effective ﬂux analysis
The control effective ﬂux (CEF) of a reaction represents the
weighted sum of all the ﬂuxes of that reaction observed in all the
possible routes (elementary ﬂux modes). So it can be considered
as the quantiﬁer of importance of a reaction at steady states. In lit-
erature, the control effective ﬂux values were used in the identiﬁ-
cation of enzymes that can serve as potential drug targets [34,38].
The CEF calculation necessitates the deﬁnition of substrate up-
take reaction and objective reactions. The substrate uptake reac-
tion is chosen to be the 11th reaction catalyzed by Serine
Palmitoyl Transferase, since it is the pioneering reaction of the de
novo sphingolipid synthesis. In fact the substrates to the sphingo-
lipid metabolism could have been selected as serine and Pal-CoA,
but aswe couldnot discriminatebetween the two in termsof impor-
tance, the next step that is the initial step of de novo synthesis is se-
lected as the substrate uptake reaction. The objective reaction issue
is resolved by taking into account the key metabolite set employed
previously in elementary ﬂux mode analysis. The reactions synthe-
sizing DHCer and PHCer are selected (r23 and r24) as objective reac-
tions. They serve the aim of accumulation of ceramide in cancer
therapy via the manipulation of the sphingolipid pathway. Another
facet of the same cancer therapy approach is the depletion of DHS-P
and PHS-P, this fact is represented in the objective reaction set by
including reactions 17 and 18. Therefore, the ﬁrst objective function
set consists of reactions 17, 18, 23 and 24. The second set addition-
ally contains reactions 14 and 19, converting DHS-P and PHS-P back
to the long chain bases. However, the two objective reaction sets
make no difference in terms of the consequences so one of themwill
be discussed in the following sections.Fig. 3. The relative scores of the control coefﬁcients obtained from the ﬁrst selection al
coefﬁcient and ﬂux control coefﬁcient scores of the selected 16 critically important reac3. Results
Ceramide and sphingosine-1-phosphate, being the sphingolipid
rheostat, are known to play critical roles in cell proliferation and
cell’s death. This fact about the two opposing signaling molecules
leads us to investigate the effects of all ceramide related metabo-
lites using metabolic control analysis and metabolic pathway
analysis.
3.1. Drug target identiﬁcation by metabolic control analysis
The discovery of the key enzymes functioning in the sphingo-
lipid metabolism is essential for both understanding the metabo-
lism and identifying drug targets for cancer therapy. The control
coefﬁcients belonging to the metabolic system given in Table 1
are used to identify the critically important enzymes that can be
used as potential drug targets in future applications. A high con-
centration control coefﬁcient (CCC) indicates that a change in the
enzyme concentration is strongly reﬂected in the desired metabo-
lite concentration. For analyzing and processing the CCCs, the set of
metabolites is grouped into two parts as they lead to different cel-
lular processes. The ‘tumor suppressor’ lipids (DHS, PHS, DHCer,
PHCer, complex sphingolipids) are examined in a different cate-
gory than the ‘‘tumor-promoting’ lipids of DHS-P and PHS-P. The
enzymes that catalyze the reactions containing this set of metabo-
lites and the related ﬂuxes and also have high control coefﬁcients
are selected as a good starting point in drug target identiﬁcation.
The ultimate drug designed to target the enzyme with high or opti-
mum control coefﬁcient is expected to have an efﬁcient outcome
that can be achieved by a small concentration introduced to the
organism.
3.1.1. Selection algorithms (SA)
Using the ﬁrst selection algorithm, the following enzymes are
identiﬁed as candidates for being potential drug targets (Fig. 3):
palmitoyl-coenzyme A synthase (r1), glycerol-3-phosphate
acyltransferase (r2), inositol-1-phosphate synthase (r6), phospho-
serine-phosphatase (r9), acyl-coenzyme A binding protein (r12),
serine hydroxymethyl transferase (r10), serine palmitoyltransfer-
ase (r11), acetyl-coenzyme A synthetase (r34), phosphatidategorithm utilizing a global threshold value. On the insert, the concentration control
tions are ranked and shown on a bar graph representation.
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phoinositol kinase (r7), 4-hydroxylase (r21), CDP-diacylglycerol
synthase (r4), phosphatidylinositol synthase (r5), in the order of
importance [The enzyme names are taken from [19].]. By exam-
ining Fig. 3, it can be seen that the critically signiﬁcant candidate
enzymes for being potential drug targets coincide for both con-
centration and ﬂux control coefﬁcients. Although the analysis of
relative concentration control coefﬁcient (CCC) scores indicates
that the enzymes glycosylphosphatidylinositol (GPI) remodelase
and IPC synthase catalyzing the 27th and 30th reactions can also
be considered as signiﬁcant, the relative ﬂux control coefﬁcient
(FCC) scores of the reactions 27 and 30 are less than 0.5, namely
0.467 and 0.433, respectively. An FCC of 0.433 means that a
change in the concentration of IPC synthase (rxn 30) affects 13
out of 30 reaction ﬂuxes.Fig. 4. The relative scores of control coefﬁcients obtained from the second selection algor
and ﬂux control coefﬁcient scores of the 10 critically important reactions are ranked an
Fig. 5. The graphical representation of the ‘average’ relative weights of both concentratio
r2, r9 and r34) compose a small subset of the previously identiﬁed reaction sets and shoIn the second algorithm the use of local thresholds caused the
limit of enzyme selection to increase from 0.4 to 0.8, meaning that
the enzymes manipulating more than 80% of 12 critical metabo-
lites and 30 reactions are identiﬁed as candidates of drug targets.
The concentration and ﬂux control coefﬁcients again point out to
the same candidate enzymes (Fig. 4). The candidate set includes
the enzymes of the reactions 1, 2, 3, 6, 9, 10, 11, 12, 16 and 34.
The second algorithm gives a more reﬁned set of enzymes as
expected.
The important reactions (r1, r2, r9 and r34) obtained from the
third algorithm with ‘average relative’ weights of control coefﬁ-
cients compose a small subset of the previously identiﬁed reaction
sets (Fig. 5). These four reactions are related to the production and
consumption of the fatty and amino acids required for the initia-
tion of sphingolipid synthesis in S. cerevisiae.ithm utilizing a local threshold value. On insert, the concentration control coefﬁcient
d shown on a bar graph representation.
n and ﬂux control coefﬁcients (third algorithm). The important reactions selected (r1,
wn in the insert.
Table 4
Relative weights of concentration control coefﬁcients of potential drug target
enzymes identiﬁed by apoptosis speciﬁc analysis.
DHCer PHCer
R2 1.0000 R27 1.0000
R9 0.8503 R34 0.9782
R34 0.6460
R1 0.5538
R12 0.4796
R6 0.4777
PHS-P DHS-P
R2 1.0000 R2 1.0000
R9 0.8524 R9 0.8627
R1 0.5670 R1 0.6312
R34 0.5331 R21 0.5550
R12 0.4910 R12 0.5465
R6 0.4683 R6 0.4713
R11 0.4560
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In apoptosis speciﬁc analysis (3rd algorithm), the constructed
critical metabolite set is partitioned into two parts according to
the knowledge about the action of metabolites on apoptosis in
mammalian cells. The CCCs of the phosphorylated forms of the
long chain bases are examined separately from that of the DHCer
and PHCer utilizing the matrix of ‘relative’ weights of the control
coefﬁcients. Consequently, the enzymes catalyzing the reactions
1, 2, 6, 9, 11, 12, 21, 27 and 34 are selected as candidates for being
drug targets (Table 4 and Fig. 6).
When the signs of the control coefﬁcients are also taken into ac-
count instead of the absolute values, the activities of the enzymes
belonging to the reactions 6, 9, 11 and 12 have to be decreased to
obtain a decrease in the concentrations of DHS-P and PHS-P. The
increase in the activities of the enzymes catalyzing the reactions
1, 2, 21 and 34 are found to cause negative inﬂuences on the con-
centrations of phosphorylated sphingoid bases of S. cerevisiae.
When the signs of ﬂux control coefﬁcients and their effects on
ceramides are considered it can be seen that the enzymatic activity
of reaction 34 should be increased in order to have an increase inFig. 6. The relative weights of concentration control coefﬁcients of phosphorylated forms
The enzymes catalyzing the reactions 1, 2, 6, 9, 11, 12, 21, 27 and 34 are selected as canthe concentrations of both ceramides (DHCer and PHCer) in S. cere-
visiae, whereas the enzyme activity of reaction 27 should be de-
creased to obtain a similar effect on ceramide concentration.
Moreover, the enzymes catalyzing the reactions 6, 9, and 12 have
negative effects and those catalyzing the reactions 1 and 2 have po-
sitive effects on DHCer but they have almost no inﬂuence on the
concentration of PHCer.
3.1.3. Perturbations on candidate enzymes
Metabolic control analysis indicates that in order to be utilized
in a cancer therapy approach (increasing ceramide concentration
and decreasing phosphorylated long chain base concentrations),
the activities of the enzymes catalyzing reactions 1, 2, 21 and 34
should be increased while the enzymatic activities belonging to
reactions 6, 9, 11, 12, and 27 should be reduced.
The effects of these enzymes were studied at a 15% perturbation
in their activities. The change in enzyme activities is kept low as it
is required that the ultimate goal (i.e. ceramide accumulation)
should be attained by a minimum disruption of the rest of the
sphingolipid metabolism. The simulation results were examined
using the relative changes in the DHCer, PHCer, DHS-P and PHS-P
concentrations with respect to the wild type concentrations at
the 24th hour of perturbation (Table 5).
More than 50% increases with respect to the wild type are
reached in DHCer concentrations (except for the enzymes catalyz-
ing reactions 21, 27 and 34) (Table 5). The most effective potential
drug target enzyme for DHCer is glycerol-3-phosphate acyltrans-
ferase (r2) with a 92.23% increase. The most effective enzyme that
can be utilized as a candidate drug target for PHCer accumulation
is the enzyme catalyzing reaction 27 with a 37.95% increase in the
metabolite concentration. When the changes attained with the
same enzymatic manipulations (15% increase/decrease) are com-
pared for the two ceramides, it can be seen that DHCer is almost
all the times more vulnerable to perturbations whereas PHCer is
more robust. This result may indicate the biological signiﬁcance
of PHCer in S. cerevisiae cells. The critically important components
of metabolic networks should be robust to alterations [39].
Palmitoyl-coenzyme A synthase (r1), glycerol-3-phosphate acyl-
transferase (r2), phosphoserine-phosphatase (r9) and acyl-coen-of long chain bases, dihydroceramide and phytoceramide for the selected enzymes.
didates for being drug targets in apoptosis speciﬁc analysis.
Table 5
The perturbation studies on candidate enzymes. The effect of 15% perturbations in candidate enzymes on key metabolite concentrations at the 24th hour of the simulations. The
most effective changes in each key metabolite are highlighted.
Concentrations r1 + r2 + r21 + r34 + r6  r9  r11  r12  r27  WT
@ 24 h
DHCer 0.0670 0.0767 0.0263 0.0580 0.0672 0.0730 0.0609 0.0667 0.0441 0.0399
% Change 67.92 92.23 34.09 45.36 68.42 82.96 52.63 67.17 10.53
DHCer
PHCer 0.0374 0.0333 0.0529 0.0544 0.0432 0.0351 0.0430 0.0375 0.0727 0.0527
% Change 29.03 36.81 0.38 3.23 18.03 33.40 18.41 28.84 37.95
PHCer
DHS-P 0.0006 0.0006 0.0008 0.0010 0.0008 0.0006 0.0008 0.0006 0.0010 0.0010
% Change 40.00 40.00 20.00 0.00 20.00 40.00 20.00 40.00 0.00
DHS-P
PHS-P 0.0010 0.0006 0.0052 0.0031 0.0016 0.0007 0.0016 0.0010 0.0051 0.0050
% Change 80.00 88.00 4.00 38.00 68.00 86.00 68.00 80.00 2.00
PHS-P
IPC 0.1471 0.1622 0.0893 0.1583 0.0973 0.1570 0.1438 0.1469 0.1643 0.1151
% Change 27.80 40.92 22.42 37.53 15.46 36.40 24.93 27.63 42.75
IPC
MIPC 0.1877 0.2029 0.1255 0.1989 0.1768 0.1976 0.1843 0.1874 0.2050 0.1541
% Change 21.80 31.67 18.56 29.07 14.73 28.23 19.60 21.61 33.03
MIPC
M(IP)2C 0.0124 0.0128 0.0103 0.0127 0.0091 0.0127 0.0123 0.0124 0.0129 0.0113
% Change 9.73 13.27 8.85 12.39 19.47 12.39 8.85 9.73 14.16
M(IP)2C
Table 6
The calculated control effective ﬂux (CEF) values for the internal ﬂuxes excluding the
transport reactions. The normalized CEF values with respect to the maximum CEF of
internal ﬂuxes are given in the second column. The ﬁrst 10 reactions are highlighted.
Reactions CEF Normalized
CEF
Reactions CEF Normalized
CEF
34 11.9544 1.00 26 1.1521 0.10
35 10.6808 0.89 6 1.1358 0.10
1 7.5022 0.63 60 1.1358 0.10
9 4.0306 0.34 40 1.1330 0.09
13 4.0000 0.33 42 1.1330 0.09
2 3.5022 0.29 43 1.1008 0.09
4 3.3047 0.28 44 1.1008 0.09
5 3.2741 0.27 17 0.9297 0.08
30 3.2647 0.27 50 0.9297 0.08
390 2.9660 0.25 24 0.7618 0.06
29 2.6435 0.22 25 0.5586 0.05
39 2.5272 0.21 27 0.3245 0.03
20 2.4725 0.21 410 0.3084 0.03
32 2.2348 0.19 380 0.2987 0.02
33 2.2348 0.19 450 0.2114 0.02
15 2.0972 0.18 3 0.1975 0.02
37 1.7652 0.15 41 0.1207 0.01
370 1.7652 0.15 38 0.1163 0.01
23 1.5619 0.13 45 0.0862 0.01
490 1.5246 0.13 8 0.0306 0.00
21 1.5083 0.13 16 0.0306 0.00
18 1.3051 0.11 10 0.0000 0.00
36 1.2737 0.11 12 0.0000 0.00
49 1.2735 0.11 22 0.0000 0.00
7 1.2368 0.10 28 0.0000 0.00
14 1.1675 0.10 31 0.0000 0.00
19 1.1675 0.10
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centration of DHS-P. When PHS-P is considered a 15% increase in
the activity of glycerol-3-phosphate acyltransferase (r2) is found
to produce an 88% decrease in PHS-P concentrations after 24 h
from the perturbation (Table 5). As it can be seen from Table 5,
the manipulation of the selected enzyme activities gives the de-
sired end results, i.e. increase in DHCer and PHCer concentrations
and decrease in DHS-P and PHS-P concentrations as required for
the application of the novel cancer therapy approach.
3.2. Drug target identiﬁcation by metabolic pathway analysis
Metabolic pathway analysis was performed for the improved
system of reactions which are shown in Fig. 2. The newly devel-
oped metabolic pathway was constructed in such a way that the
very ﬁrst substrates and the end products are consistent with the
system employed in the metabolic control analysis. Since the met-
abolic pathway analysis is a stoichiometric tool the reactions in the
improved model are stoichiometrically balanced including the
cofactors and hydrogen, and the lumped reactions are decom-
posed. The current sphingolipid pathway used in metabolic path-
way analysis has 54 reactions and 41 transport reactions and 67
metabolites.
3.2.1. Elementary ﬂux modes (EFMs)
Elementary ﬂux modes are here used to identify the function-
ally and structurally important enzymatic steps in the S. cerevisiae
sphingolipid metabolism and hence degree of control of reactions.
The present system of sphingolipid reactions resulted in 2446 ele-
mentary ﬂux modes which were studied in terms of two different
approaches, i.e. common reactions among selected EFMs and con-
trol effective ﬂuxes.
The key metabolites, DHCer, PHCer, DHS-P and PHS-P, are found
to participate in 164 out of 2446 calculated EFMs. The common
reactions available in all the 164 EFMs were reactions 1, 2, 9, 11,
13, 15, 20, 23, 26, 32 and 33. Furthermore the transport reactions
of adenosine triphosphate (ATP), 3-phosphoserine (3PS), glycerol-
3-phosphate (G3P), cytidine triphosphate (CTP), reduced nicotin-
amide adenosine dinucleotide phosphate (NADPH), oxygen (O2),adenosine monophosphate (AMP), diphosphate (DP), phosphate
(P), cytidine monophosphate (CMP), carbon dioxide (CO2), nicotin-
amide adenosine dinucleotide phosphate (NADP) and phosphatidyl
ethanolamine (PE) were also identiﬁed as common reactions
occurring in all the selected EFMs of the key metabolites set.
In an additional EFM analysis, a second set of critical metabo-
lites were constructed where the end products of the sphingolipid
pathway that is the complex sphingolipids, IPC, MIPC and M(IP)2C
synthesized from both DHCer and PHCer were also taken into con-
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no EFMs in which all the constituent metabolites of the second set
participated.
3.2.2. Control effective ﬂuxes (CEFs)
The information for the identiﬁcation of potential drug targets
was extracted from the determined elementary ﬂux modes via
control effective ﬂux (CEF) analysis. The calculated CEF values for
the internal ﬂuxes excluding the transport reactions are given in
Table 6 using the ﬁrst objective function set. The ﬁrst 10 reactions
were identiﬁed as candidates of potential drug target enzymes. The
candidate enzymes catalyze the reactions 34, 35, 1, 9, 13, 2, 4, 5, 30
and 390 in the order of their importance.
As a concluding remark that can be dictated from the metabolic
pathway analysis results, the reactions 1, 2, 4, 5, 9, 11, 13, 15, 20,
23, 26, 30, 32, 33, 34, 35 and 390 may be stated to be potential drug
targets (Table 7). When the candidate enzymes proposed for being
drug targets achieved by metabolic pathway analysis are put side
by side with the known potential drug target enzymes in pre-clin-
ical or clinical development stages of drug discovery, it can be seen
that metabolic pathway analysis can identify the known targets
such as the enzymes of reactions 11, 15, 20 and 23. The mathemat-
ical tools’ efﬁciency for drug target identiﬁcation performed in this
study is thus validated by the clinically available drugs.
4. Discussion
We combined the results of the two mathematical tools (MCA
and MPA) to obtain a more complete view and reached an ultimate
set of potential drug target enzymes (Table 7). These common en-
zymes that are indicated by both MCA and MPA results are of the
reactions 1, 2, 9, 11 and 34 and they are identiﬁed by at least four
out of ﬁve of the methods discussed here. Moreover, if the target
enzymes that appear in at least one of the MCA selection algo-
rithms and one of the MPA computations are also included in this
ﬁnal set, the enzymes catalyzing the reactions 4, 5 and 11 emerge
to be the additional candidates. Besides these, the known drug tar-
get enzymes from the literature that are identiﬁed by the MPA re-
sults could also be included in the concluding set (r11, r15, r20, r23).
The target enzymes that are determined by all the three selection
algorithms of MCA but not MPA, i.e. enzymes belonging to reac-
tions 6 and 12, can be added to the candidate list due to their reli-
ability by passing all selection criterions of MCA. Another reason
for including reaction 6 in the ultimate set of potential drug targets
is that the manipulation of the enzyme activity of reaction 6 does
not disturb the complex sphingolipid concentrations much with
the percent change values of 15.46%, 14.73% and 19.47% for
the IPC, MIPC and M(IP)2C, respectively (Table 5). An ideal drug
is expected not to affect the metabolism other than its targets.Table 7
Potential drug targets that are determined using ﬁve different computational tools. Three
using global threshold (MCA S.C. 1), local threshold (MCA S.C. 2) and apoptosis speciﬁc an
analysis; calculation of elementary ﬂux modes (MPA EFM) and control effective ﬂux values
are also indicated as bold.
Reactions 1 2 3 4 5 6 7 9 10 11 12 13 15
MCA
S.C. 1
+ + + + + + + + + + +
MCA
S.C. 2
+ + + + + + + +
MCA
S.C. 3
+ + + + + +
MPA
EFM
+ + + + + +
MPA
CEF
+ + + + + +Although not identiﬁed by MPA results, reactions 21 and 27 from
MCA results are also taken into account due to reaction 27’s essen-
tial effect on PHCer accumulation (37.95% change, Table 5) and
reaction 21’s almost null effect on complex sphingolipids. The
manipulation of the enzyme activity of reaction 21 has its desired
effects on ceramide accumulation and long chain base phosphate
depletion but it does not change the complex sphingolipid content
of the cell with respect to wild type, i.e. 22.42%, 18.56% and
8.85% alterations in IPC, MIPC and M(IP)2C’s concentrations,
respectively (Table 5).
The drug targets proposed in this study are found to be more
conserved than the other enzymes in the sphingolipid network
(Supplementary Table 1).4.1. Biological meaning of the potential drug targets
The ﬁrst reaction catalyzed by palmitoyl-coenzyme A synthase,
supplies the system with the fatty acid, Pal-CoA, which is needed
for the very ﬁrst step of de novo sphingolipid synthesis, i.e. conden-
sation of Pal-CoA and serine in the endoplasmic reticulum to yield
3-ketodihydrosphingosine. The signiﬁcance of the glycerol-3-phos-
phate acyltransferase enzyme catalyzing the second reaction
comes from the fact that the second reaction is a branch point
for the consumption of Pal-CoA. Pal-CoA can enter the de novo
sphingolipid synthesis via reaction 11 or it can shift to the fatty
acid metabolism via reaction 2. This enzyme is on the path of sup-
plying substrates to the sphingolipid metabolism. The cell decides
to enhance the production of either sphingolipids or fatty acids at
this branch point. Cytidine diphosphate-diacylglycerol (CDP-DAG)
synthase (r4) and phosphatidylinositol synthase (r5) have roles in
the phospholipids pathway and they serve as the source of PI re-
quired for the synthesis of complex sphingolipids. Their impor-
tance relies on the fact that they function on the path of complex
sphingolipid synthesis. 4-Hydroxylase (r21) is also proposed to be
a potential drug target according to the results of metabolic control
analysis; this reaction yields the conversion of DHS to PHS. In some
literature resources [5,6,16,40], it is reported that DHCer is not bio-
logically active in mammalian cells, whereas the same remark can-
not be stated for S. cerevisiae at least with the experimental
evidence available currently [41–43] reporting the biological func-
tion of DHCer in apoptosis in human cancer cells. The signiﬁcance
of the conversion of DHS to PHS in S. cerevisiae may emphasize a
more active role to PHS when compared with DHS just as in mam-
malian cells. Acetyl-coenzyme A synthetase is the enzyme catalyz-
ing the 34th reaction, functioning in the fatty acid synthesis. The
precursor fatty acid that is necessary for the production of the ini-
tiator fatty acid Pal-CoA of the sphingolipid pathway is produced
by reaction 34. The signiﬁcance and controlling effect of the en-
zyme is due to this reason.selection algorithms are employed for the examination of metabolic control analysis;
alysis (MCA S.C. 3). Two different computations are performed in metabolic pathway
(MPA CEF). The enzymes that are known drug targets in clinical development stages
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tion 6 that supplies inositol to the sphingolipid metabolism. In the
model system under investigation, reaction 6 is the only source for
inositol and it was classiﬁed as a critically important enzymatic
step. Inositol is essential for the synthesis of complex sphingolipids
because it is the precursor metabolite of phosphatidyl inositol.
Phosphoserine-phosphatase functions as the supplier of serine
(r9) is necessitated for the beginning of de novo sphingolipid pro-
duction. Serine palmitoyltransferase enzyme catalyzing reaction
11 is one of the drug targets described in the literature [7,9], drugs
targeting this enzyme are now at pre-clinical or clinical develop-
ment stages. This step is also identiﬁed in this study as one of
the signiﬁcant control points that can be used in cancer therapy.
The importance of this enzymatic step comes from the fact that
it is the initial reaction of the de novo sphingolipid synthesis.
Twelfth and 27th reactions are two exchange reactions which de-
plete the essential fatty acid needed for the initiation of de novo
sphingolipid synthesis: Pal-CoA and PHCer, respectively. Since
these reactions are the direct consumers of the two essential
metabolites of sphingolipid metabolism, the two exchange reac-
tions are speciﬁed and proposed to be candidates for being poten-
tial drug targets. Acyl-coenzyme A binding protein is responsible
for the exchange of Pal-CoA in reaction 12 and it is the GPI remode-
lase enzyme that executes reaction 27. Reactions 15 and 20 are cat-
alyzed by sphingolipid long chain base kinase and responsible for
the formation of DHS-P and PHS-P, respectively. These reactions
are the ones that directly produce the phosphorylated forms of
the long chain bases.5. Conclusion
When the two systems biology tools employed in the current
study are compared in terms of their potency in potential drug tar-
get identiﬁcation, it can be seen that metabolic pathway analysis
results overlap more with the known drug targets in the literature.
Metabolic control analysis results, on the other hand, are more
informative since one can gather information about the direction
of action, i.e. whether one should inhibit or activate the target en-
zyme. Thus, MCA results go one step further on the way to drug
discovery and drug design.
In conclusion, the enzymes catalyzing the reactions 1, 2, 4, 5,
6, 9, 11, 12, 15, 20, 21, 23, 27 and 34 are proposed as putative
drug targets by both MCA and MPA. The activities of palmitoyl-
coenzyme A synthase (r1), glycerol-3-phosphate acyltransferase
(r2), CDP-DAG synthase (r4), phosphatidylinositol synthase (r5),
4-hydroxylase (r21), ceramide synthase (r23) and acetyl-coenzyme
A synthetase (r34) should be increased to obtain the ceramide
accumulation and long chain base phosphate depletion and the
activities of inositol-1-phosphate synthase (r6), phosphoserine-
phosphatase (r9), serine palmitoyl transferase (r11), acyl-coe-
nyzme A binding protein (r12), sphingolipid long chain base
kinase (r15 and r20) and GPI remodelase (r27) should be decreased
in order to reach the same cancer therapy essentials. Integration
of the results of the two theoretical frameworks as we have done
in this study can be utilized in future in other drug target iden-
tiﬁcation studies.
In order to obtain more efﬁcient drugs in cancer therapy; drugs
targeting two or more enzymes may be developed or two or more
drugs may be utilized at the same time course. There is clinical evi-
dence of using drugs [7,9] both inhibiting ceramide catabolism and
generating ceramide simultaneously.Conﬂict of interest
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